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Objective: Cardiopulmonary bypass is a potent stimulus for activation of
procoagulant pathways. Heparin, the traditional antithrombotic agent,
however, is often associated with increased perioperative blood loss
because of its multiple sites of action in the coagulation cascade and its
antiplatelet and profibrinolytic effects. Furthermore, heparin-mediated
immunologic reactions (that is, heparin-induced thrombocytopenia)
may contraindicate its use. Cardiopulmonary bypass with a selective
factor IXa inhibitor was tested to see whether it could effectively limit
bypass circuit/intravascular space thrombosis while decreasing ex-
travascular bleeding, thereby providing an alternative anticoagulant
strategy when heparin may not be safely administered. Methods: Active
site-blocked factor IXa, a competitive inhibitor of the assembly of factor
IXa into the factor X activation complex, was prepared by modification
of the enzyme’s active site by the use of dansyl glutamic acid-glycine-
arginine-chlormethylketone. Twenty mongrel dogs (five were given stan-
dard heparin/protamine; 15 were given activated site-blocked factor IXa
doses ranging from 300 to 600 mg/kg) underwent 1 hour of hypothermic
cardiopulmonary bypass, and blood loss was monitored for 3 hours after
the procedure. Results: Use of activated site-blocked factor IXa as an
anticoagulant in cardiopulmonary bypass limited fibrin deposition
within the extracorporeal circuit as assessed by scanning electron
microscopy, comparable with the antithrombotic effect seen with hepa-
rin. In contrast to heparin, effective antithrombotic doses of activated
site-blocked factor IXa significantly diminished blood loss in the
thoracic cavity and in an abdominal incisional bleeding model. Conclu-
sion: These initial studies on the dog suggest that administration of
activated site-blocked factor IXa may be an effective alternative antico-
agulant strategy in cardiopulmonary bypass when heparin is contrain-
dicated, affording inhibition of intravascular/extracorporeal circuit
thrombosis with enhanced hemostasis in the surgical wound. (J Thorac
Cardiovasc Surg 1998;115:1179-88)
Cardiopulmonary bypass (CPB) presents a substan-tial prothrombotic stimulus in cardiac operations;
thus its successful performance requires potent anti-
coagulation.1 Heparin, the traditional antithrombotic
agent, however, is not without untoward side effects.
Its multiple sites of action in the coagulation cascade
and its profibrinolytic and antiplatelet effects contrib-
ute to an adverse bleeding diathesis and potential
morbidity and death in many patients undergoing
CPB.1-4 Furthermore, complications associated with
the use of heparin, including heparin-induced throm-
bocytopenia with potential for pathologic thrombosis,
also render its use contraindicated in a subset of
patients. The need for pharmacologic reversal of hep-
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arin effect with protamine may itself contribute to
additional perioperative morbidity with the possibility
of life-threatening protamine allergy and subsequent
hemodynamic collapse.5, 6
Although multiple strategies to perform CPB in
the absence of heparin have been suggested (low-
molecular weight heparins, thrombin inhibitors, ilo-
prost, ancrod, orgaran, or dermatan sulfate), none
are routinely used in the clinics in the United States,
likely because their use has been associated with
such complications as potential for sensitization,
cross-reactivity with heparin, profound hemody-
namic instability, or excessive bleeding.7-13 Other
strategies, such as addition of antifibrinolytic agents,
although reducing blood loss, nevertheless do not
obviate the use of heparin/protamine.14-16
In situations where the use of heparin is relatively
contraindicated, we have sought an alternative anti-
coagulant that would selectively inhibit intravascular
coagulation, resulting from the contact of circulating
blood with extracorporeal membranes, filters, and
tubing, while enhancing extravascular hemostasis
with decreased blood loss in the surgical wound.
These considerations led us to focus on the role and
unique location of factor IX/IXa in the coagulation
cascade.
Factor IXa expresses its procoagulant activity
after incorporation into the intrinsic factor X acti-
vation complex, consisting of factors IXa, VIII(a)
assembled on an appropriate cellular surface in the
presence of calcium ions. This complex then acti-
vates factor X, and the newly formed factor Xa then
becomes integrated into the prothrombinase com-
plex, thereby generating thrombin. In the presence
of relatively low levels of tissue factor, such as that
present in the intravascular space/extracorporeal
circuitry during the initial phase of CPB, inhibition
of the participation of factor IX/IXa would prevent
activation of coagulation mediated by both the
tissue factor–factor VIIa and contact (intrinsic)
pathways. However, in the presence of high levels of
tissue factor, such as that present on the cut surface
of the sternum and in the pericardium, the tissue
factor–factor VIIa pathway would directly activate
factor X, thus resulting in the generation of throm-
bin and clot formation in the surgical wound.17
Because selective reversible inhibitors of factor
IXa have not been developed, we prepared active
site-blocked factor IXa (IXai), in which the active
site residues serine 376 and histidine 221 were
acetylated and alkylated, respectively, with dansyl-
Glu-Gly-Arg chloromethylketone, and used this
agent as a competitive inhibitor of the assembly of
factor IXa into the intrinsic factor X activation
complex.18, 19 Indeed, IXai has already been tested
as a selective anticoagulant in an electric-current
canine coronary thrombosis model.20, 21 In those
studies, compared with dogs receiving active site-
Fig. 1. MCCT. A, Assay procedure. Factor IX-deficient plasma was incubated with Celite (0.024 mol/L in
barbital buffer [0.05 mol/L]) in silicone-coated glass tubes for 2 minutes in a shaking water bath at 37° C.
An optimized concentration of cephalin (1:32; B) in barbital buffer (0.05 mol/L) was added, along with
control or test-dog plasma (0.05 ml) and calcium chloride (0.001 mol/L). Time to clot formation was then
visually determined. C, Determination of the limit of detection of the MCCT was performed with different
concentrations of IXai and normal dog plasma. Data were plotted as log MCCT versus log [IXai] of each
value. The limit of detection in this assay is 0.06 mg/ml.
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blocked Xa, dogs receiving IXai manifested inhibi-
tion of intravascular thrombosis with preservation of
extravascular hemostasis (as demonstrated in an
incisional abdominal wound model).
In this report, we demonstrate that administration
of IXai in canine CPB results in the inhibition of
intravascular thrombosis within the extracorporeal
circuit, with diminished bleeding tendency within
the surgical wound. These data suggest that use of
IXai may be a potential alternative anticoagulant
strategy in CPB, especially in situations where the
use of heparin is relatively contraindicated.
Materials and methods
Preparation and purification of IXa/IXai. Factor IXai
was prepared and characterized as described in the ap-
pendix.
CPB in dogs. Twenty mongrel dogs (27 to 35 kg)
underwent CPB for 1 hour after induction of anesthesia
with isoflurane and appropriate endotracheal ventilation.
The heart was suspended in a pericardial cradle after
median sternotomy. Anticoagulant (either factor IXai
[range 300 to 600 mg/kg)] or heparin 300 IU/kg) was
infused intraatrially; CPB was established with cannula-
tion of the right atrial appendage and ascending aorta (70
ml/kg/min, 32° C, mean arterial pressure 55 to 70 mm Hg).
CPB with a roller head pump (Stockert Instrumente,
Munich, Germany) primed with lactated Ringer’s solution
(1 liter) and a Cobe membrane lung oxygenator (Cobe
Cardiovascular, Inc., Arvada, Colo.) with sterile surgical
grade Tygon tubing/filters (Norton Performance Plastics,
Akron, Ohio) was maintained for 1 hour. The aorta was
crossclamped, and the heart was arrested with cold crys-
talloid cardioplegic solution. An aortotomy was per-
formed to simulate an aortic valve repair. Throughout the
procedure a left atrial vent catheter was attached to a
cardiotomy sucker. The pericardium was continuously
evacuated through an additional cardiotomy sucker so as
not to allow pericardial pooling of blood. The aortotomy
was subsequently repaired after appropriate deairing; the
heart was rewarmed, and the aortic crossclamp was re-
leased. Dogs were then weaned from CPB and decannu-
lated.
In dogs treated with heparin, protamine (2 mg/kg) was
administered intravenously at the termination of CPB.
After cessation of CPB, animals were observed for up to
3 hours to measure the extent of blood loss. At hourly
intervals after bypass, blood that pooled in the pericardial
and pleural spaces was suctioned, and the amount ob-
tained was carefully quantitated and recorded. Continu-
ous hemodynamic measurements were made and re-
corded before, during, and up to 3 hours after institution
of CPB. One surgeon performed all of the experiments;
no modifications of the operating technique were made
throughout the study.
The experimental animals were divided into five groups.
Group 1 (n 5 5), the control group, received standard
doses of heparin/protamine (300 IU/kg and 2 mg/kg,
respectively). Animals treated with IXai received a single
dose of IXai (group 2 [n 5 3], 300 mg/kg; group 3 [n 5 3],
360 mg/kg; group 4 [n 5 6], 460 mg/kg; and group 5 [n 5
3], 600 mg/kg). No pharmacologic reversal was adminis-
tered to animals treated with IXai.
All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” formulated
by the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Sciences and pub-
lished by the National Institute of Health (NIH publica-
tion 86-23, revised 1985). This study was approved by the
Columbia University Institutional Animal Review Com-
mittee and was conducted according to Columbia Univer-
sity policy.
Assessment of fibrin deposition in the CPB tubing and
filters. At termination of CPB, the tubing and filters were
removed and subjected to analysis by scanning electron
microscopy as previously described.22
Analysis of blood samples and tissue. Routine hema-
tologic analysis was performed before the initiation of
CPB, every 15 minutes during CPB, and then at hourly
intervals after CPB to determine hemoglobin and hemat-
ocrit values, levels of platelets and fibrinogen, white blood
cell count, prothrombin time, activated partial thrombo-
plastin time, and activated clotting time (ACT; Interna-
tional Technidyne, Edison, N.J.). Celite (Celite Corpora-
tion, Quincy, Mass.) ACT was evaluated on a Hemachron
model 801 (International Technidyne, Edison, N.J.). After
the dogs were killed, necropsy was performed; the heart,
lungs, liver, and kidney were removed, fixed in formalin
(10%), and examined by histochemistry with hematoxylin
Fig. 2. Purification of factor IXai from Proplex. Factor
IX was purified from Proplex and activated with factor
XIa as described. IXa was then reacted with dansyl-Glu-
Gly-Arg-chloromethylketone to yield IXai. Factors IX,
IXa, and IXai were run on SDS-PAGE under nonreduc-
ing or reducing conditions as indicated: Lane 1 (10 mg);
lane 2 (10 mg); lane 3 (10 mg); lane 4 (15 mg); lane 5 (10
mg); and lane 6 (15 mg).
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and eosin for evidence of clot/fibrin deposition and the
presence of microemboli or bleeding.
Platelet aggregation studies. Platelet-rich plasma was
isolated from blood collected from a normal volunteer (no
aspirin intake for at least .7 days), and platelet aggrega-
tion was measured in response to epinephrine (100 mm)
or collagen (190 mg/ml) on a PAP 4A aggregometer
(Bio/Data, Horsham, Pa.) as previously described23 in the
presence of various concentrations of IXai, heparin, or a
combination of IXai/heparin.
Assessment of extravascular bleeding tendency. The
bleeding tendency at extravascular sites was assessed with
a modified incisional bleeding time as previously de-
scribed.20 Briefly, a uniform abdominal wall incision (1 cm
deep, 5 cm long) was made, and a preweighed 4 3 4 inch
gauze was inserted for 5 minutes. The gauze was then
removed and reweighed, and the weight of blood loss
quantitated. Measurements were taken at baseline, imme-
diately after institution of CPB, and at one-half hour
intervals until the animal was killed.
The modified cephalin clotting time (MCCT). To de-
tect levels of IXai in plasma as a means of monitoring its
use in CPB, we developed a rapid, reproducible test using
factor IX deficient plasma, Celite diatomaceous earth,
barbital buffer, calcium chloride, cephalin, and standard
dog plasma (Sigma Chemical Co., St. Louis, Mo.). Factor
IX-deficient plasma (0.1 ml) was mixed with Celite (0.024
mol/L) in barbital buffer (0.05 mol/L) in silicone-coated
glass tubes for 2 minutes in a shaking water bath at 37° C
(Fig. 1, A). To this mixture was added an optimized
concentration of cephalin (1:32) in barbital buffer (0.05
mol/L) (Fig. 1, B), control or test-dog plasma (0.05 ml),
and lastly, calcium chloride (0.001 mol/L). Time to clot
formation was then visually measured for each point. The
limit of detection of IXai in this assay was 0.06 mg/ml (Fig.
1, C).
Statistical analysis. Data are expressed as the mean 6
standard error. Serial data from each group were evalu-
ated by the repeated measures analysis of variance and
then by paired t test with the use of InStat 2.01 statistical
analysis program (Graphpad Software, San Diego, Calif.)
on a Macintosh computer (Apple Computer, Cupertino,
Calif.).
Results
IXai was prepared and purified from a mixture of
the human vitamin-K–dependent coagulation fac-
tors (factors II, VII, IX, and X; Proplex; Baxter
Fig. 3. Scanning electron microscopy of the CPB filters. Dogs were treated with IXai (460 mg/kg) or
heparin (300 IU/kg/protamine 2 mg/kg) and underwent CPB for 1 hour. At the end of CPB, the filters were
removed and subjected to scanning electron microscopy at the indicated magnifications. CPB performed
with IXai (460 mg/kg) was associated with similar amounts of clinically inapparent fibrin deposition,
compared with heparin (left panel). At 360 mg/kg IXai, visible fibrin and platelet deposition was observed
(right panel).
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Pharmaceuticals, Duarte, Calif.). Factor IX was first
purified from this material and migrated as a single
band on sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in the absence or
presence of mercaptoethanol (10%) with an appar-
ent relative molecular mass of approximately 68
kDa (Fig. 2, lanes 1 and 2, respectively). On activa-
tion of factor IX with XIa, purified factor IXa
migrated as a single band on nonreduced SDS-
PAGE gels, with a relative molecular mass of ap-
proximately 45 kDa, and as two bands, correspond-
ing to the heavy and light chains of factor IXab on
reduced gels (Fig. 2, lanes 3 and 5, respectively).
After inactivation with dansyl Glu-Gly-Arg chloro-
methylketone and extensive dialysis, the resulting
factor IXai, devoid of procoagulant activity, mi-
grated identically to IXa on SDS-PAGE (Fig. 2,
lanes 4 [nonreduced] and 6 [reduced]). Subsequent
to removal of detectable levels of endotoxin, IXai
was then tested in canine CPB.
CPB was performed in 20 dogs for 1 hour at 32° C
with standard heparin/protamine or varying doses of
IXai as an anticoagulant. Compared with dogs re-
ceiving heparin (n 5 5), dogs receiving IXai (460
mg/kg [n 5 6] and 600 mg/kg [n 5 3]) demonstrated
similar hemodynamic profiles (70 ml/kg/min flow,
32° C, 55 to 70 mm Hg mean arterial pressure), with
no evidence of increased pressures in the CPB
tubing or circuitry at any time during the procedure.
In addition, no visible clot was noted in the circuity.
However, in dogs treated with the lowest dose of
IXai (300 mg/kg [n 5 3]), a visible clot formed in the
bypass tubing along with the development of excess
line pressures, thereby necessitating premature ter-
mination of CPB. In dogs treated with IXai (360
mg/kg [n 5 3]), although a visible clot formed in the
CPB circuit/tubing, CPB was successfully main-
tained for 1 hour with no increased line pressures. In
a limited number of animals treated with the opti-
mal antithrombotic dose of IXai (460 mg/kg; 6 dogs),
CPB was extended to 1.5 hours to demonstrate the
feasibility of the use of IXai over this time period.
Similar results were found when compared to 1 hour
of CPB (data not shown).
To detect fibrin or platelet deposition within the
bypass circuit, the tubing and filters were removed
immediately on the termination of CPB and ana-
lyzed by scanning electron microscopy. CPB per-
formed with heparin or IXai (460 mg/kg or 600
mg/kg) resulted in similar levels of fibrin deposition
Fig. 4. Thoracic-cavity blood loss in dogs undergoing
CPB. Dogs underwent CPB with either IXai (300 to 600
mg/kg) or heparin/protamine for 1 hour; dogs were then
observed for 3 hours after discontinuation of CPB. At the
end of the observation period, dogs receiving heparin
accumulated 1275 6 115 ml blood in the thoracic cavity;
those dogs receiving either 360 mg/kg or 460 mg/kg IXai
accumulated significantly less blood in the thoracic cavity
(530 6 55 ml and 520 6 30 ml, respectively). At 600 m/kg
IXai, increased bleeding was observed in the thoracic
cavity (950 6 300 ml). *Indicates p , 0.05 in dogs treated
with IXai compared with heparin by analysis of variance.
Fig. 5. Incisional wound model. To establish the effects
of IXai on bleeding outside the operative field, a stan-
dardized incisional model in the abdomen was used as
described earlier. At an effective antithrombotic dose of
IXai (460 mg/kg), there was no evidence of enhanced
bleeding at the time points assessed compared to baseline.
In contrast, significantly increased bleeding was observed
after infusion of heparin during CPB, which returned to
baseline after heparin reversal with protamine. At a dose
of IXai of 600 mg/kg, significantly increased bleeding was
observed during CPB, comparable to that seen with
heparin treatment. Data are reported as means 6 stan-
dard error. *Indicates p , 0.05 in dogs treated with IXai
compared with heparin by analysis of variance.
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(Fig. 3, left panel). However, at 360 mg/kg IXai,
significantly increased fibrin and platelet deposition
was noted in the arterial filter (Fig. 3, right panel).
At an effective antithrombotic dose of IXai (460
mg/kg), no adverse effects were noted in the visceral
organs. Three hours after termination of CPB, nec-
ropsy revealed no gross or microscopic thrombosis
or bleeding in the heart, lungs, liver, or kidney in
animals treated with IXai compared with those
receiving heparin (data not shown).
We had hypothesized that an important distinc-
tion between IXai and heparin in CPB would be the
divergent effects of these agents on extravascular
hemostasis. Consistent with this hypothesis, in con-
trast with heparin-treated animals, a hemostatic clot
was observed along the cut surface of the sternum
and in surgical tissue planes throughout the proce-
dure in IXai-treated animals. Furthermore, blood
loss in the thoracic cavity was diminished in dogs
treated with IXai (in dogs treated with IXai, 360
mg/kg, 520 6 53 ml; in dogs treated with IXai, 460
mg/kg, 520 6 60 ml) compared with dogs receiving
standard heparin/protamine (1275 6 115 ml; p ,
0.05). However, at 600 mg/kg IXai, an increased
bleeding tendency was observed that was similar to
that found in animals treated with heparin (950 6
300 ml; p 5 0.2) (Fig. 4), suggesting a dose-depen-
dent effect.
Further assessment of the extravascular bleeding
tendency in dogs treated with IXai versus heparin
was demonstrated in an abdominal incision model,
essentially a modified bleeding time. On administra-
tion of IXai (460 mg/kg), significantly decreased
bleeding was observed compared with animals
treated with standard doses of heparin (Fig. 5). In
contrast, treatment with 600 mg/kg of IXai resulted
in bleeding similar to that observed with heparin
(Fig. 5). Taken together, these data suggest that
Fig. 6. Hematologic analysis. Dogs underwent CPB with either IXai (460 mg/kg) or heparin/protamine. At
the indicated times, blood was withdrawn for analysis of white blood cell count (A), hematocrit value (B),
and platelets (C). No significant differences were observed between groups. Each group represents mean
values observed in four dogs.
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compared with heparin, extravascular bleeding ten-
dency is diminished in dogs treated with effective
antithrombotic doses of IXai.
Use of IXai as an anticoagulant in CPB did not
adversely affect routinely measured hematologic val-
ues. Compared with heparin, in dogs receiving ef-
fective antithrombotic doses of IXai (460 mg/kg), no
untoward effects were observed on either white
blood cell count or hematocrit values (Fig. 6, A and
B). Levels of platelets were not significantly different
in dogs treated with IXai or heparin, although a
trend was observed toward less variability in dogs
treated with IXai (Fig. 6, C).
Platelet aggregation studies performed in the
presence of increasing concentrations of IXai (0.1 to
5.0 mg/ml) or IXai (0.4 mg/ml) in combination with
heparin (9 U/ml) revealed no abnormalities in pri-
mary or secondary wave of aggregation in response
to either epinephrine (Fig. 6, D) or collagen (data
not shown). In addition, no spontaneous aggrega-
tion was observed in the presence of IXai (0.1 to 5.0
mg/ml) or heparin/IXai (9 U/ml and 0.4 mg/ml,
respectively; data not shown).
Coagulation assays revealed that compared to
dogs treated with heparin, dogs treated with IXai
(460 mg/kg) demonstrated no significant increase in
prothrombin time (Fig. 7, A), activated partial
thromboplastin time (Fig. 7, B), or ACT (Fig. 7, C).
These findings are most likely explained by the lack
of sensitivity of these assays for assessment of effec-
tive antithrombotic doses of IXai. However, to
realistically use IXai in CPB, it would be important
to be able to rapidly and reproducibly detect the
antithrombotic activity of IXai. We therefore devel-
oped the MCCT as described earlier. Compared
with preoperative values (MCCT of 21 6 1.2 sec-
onds), after a single dose of IXai immediately before
CPB (460 mg/kg), MCCT rose to approximately 80
seconds through at least 1 hour of CPB and returned
to baseline by 3 hours after CPB (Fig. 8). MCCT for
heparin-treated dogs was more than 100 seconds
throughout bypass, returning to baseline after pro-
tamine administration (Fig. 8). Similar results were
found in dogs treated with IXai that did not undergo
any surgical procedure, with a fourfold increase in
MCCT after drug administration, which returned to
baseline by 3 hours after administration (data not
shown).
Fig. 6, cont’d. D, Platelet aggregation studies as described were performed on platelet-rich plasma from
normal volunteers in response to epinephrine (100 mm) in the presence of various concentrations of IXai:
lane 1, 5.0 mg/ml; lane 2, 1.0 mg/ml; lane 3, 0.8 mg/ml; lane 4, 0.4 mg/ml; lane 5, 0.2 mg/ml; and lane 6, 0.1
mg/ml; or in the presence of IXai/heparin: lane 7, IXai 0.4 mg/ml/heparin 9 U/ml; or heparin alone: lane
8, 13.5 U/ml; and lane 9, 9 U/ml. Arrow indicates the point at which the agonist (epinephrine) was added.
In all cases, primary and secondary waves of aggregation were normal.
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Discussion
Multiple stimuli converge in CPB to present a
potent prothrombotic stimulus.1 The use of heparin
anticoagulation successfully prevents intravascular/
extracorporeal circuit thrombosis at the expense,
however, of impaired hemostasis in the surgical
wound. In these studies, we demonstrated in a
canine model of CPB that prevention of the assem-
bly of factor IXa into the factor IXa-VIIIa-X com-
plex (factor X activation complex) on an appropri-
ate cell surface effectively permits flow of blood over
the extracorporeal circuits without increased pres-
sures or thrombus formation within the intravascu-
lar space/extracorporeal circulation. In contrast to
heparin, however, these data suggest that targeted
inhibition of the participation of factor IXa in the
procoagulant pathways enhances hemostasis in the
surgical wound, with diminished blood loss in the
thoracic cavity and in an incisional abdominal
wound model.
Despite the complex set of intrinsic (contact)/
extrinsic (tissue factor)–mediated pathway interac-
tions that together underlie the coagulopathy of
CPB, the unique position of IX/IXa in the clotting
cascade may render it an ideal target for selective
antithrombotic intervention in CPB. Indeed, multi-
ple studies24-26 have indicated an important role for
the contact system in CPB, as would be expected on
Fig. 7. Analysis of (A) prothrombin time (PT), (B) acti-
vated partial thromboplastin time (PTT), and (C)ACT
in dogs undergoing CPB. Blood was withdrawn at the
indicated times, and citrated plasma was prepared. PT
remained control in dogs treated with IXai (460 mg/kg)
and activated PTT was mildly elevated. In contrast,
dogs treated with heparin/protamine demonstrated signif-
icant elevations of PT and activated PTT. ACT values
(117 6 32.0 seconds at baseline in all dogs), which
returned to baseline after the administration of prota-
mine, rose to .480 seconds during CPB in the dogs
treated with heparin. In contrast, in dogs treated with
IXai (460 mg/kg), ACT did not rise significantly above
baseline (133 6 23.0 seconds). *Indicates p , 0.05 in dogs
treated with IXai compared with heparin by analysis of
variance.
Fig. 8. Determination of the MCCT in CPB. Dogs were
placed on CPB with an effective antithrombotic dose of
IXai (460 mg/kg), and MCCT was measured throughout
the procedure. Baseline (preoperative) MCCT was 21 6
1.2 seconds, which rose to 80 seconds after administration
of IXai. Levels returned to baseline by 3 hours after CPB.
Similarly, dogs were placed on bypass with heparin and
reversed after bypass with protamine.
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the intimate contact of circulating blood with the
extracorporeal circuitry: (1) reduced levels of factor
XII indicate early activation of the clotting system in
CPB; (2) levels of factor XIIa and factor XIIa
activity are elevated in the plasma of patients un-
dergoing CPB; and (3) factor XII/XIIa become
localized on tubing in the bypass circuit. An impor-
tant role for the extrinsic pathway in the coagulation
abnormalities observed in CPB has also been sug-
gested: low levels of tissue factor expressed by
monocytes that have adhered to the bypass circuitry
(after 2 hours) may result in selective activation of
IX by the tissue factor-VIIa pathway in that setting,
likely to be effectively inhibited by IXai.27 Further-
more, given the progressively increased expression
of endothelial tissue factor from the luminal to the
adventitial side of the blood vessel, high levels of
tissue factor in the surgical wound have critically
limited access to the intravascular space/extracorpo-
real circulation, thus precluding intravascular
thrombosis, while effecting tissue factor-VIIa-medi-
ated activation of the extrinsic pathway and extravas-
cular hemostasis, a process not affected by IXai.28, 29
Indeed, recently it has been suggested that a major
procoagulant perturbation in cardiac surgery/CPB is
the wound itself, with high levels of tissue factor noted
in the extravascular space.30
In conclusion, although we performed this proce-
dure in a limited number of dogs, these initial data
suggest that active site-blocked factor IXa might rep-
resent an alternative antithrombotic strategy in CPB,
in which decreased bleeding tendency in the surgical
wound results in the absence of apparent intravascu-
lar/extracorporeal circuit thrombosis. Studies in ba-
boons are in progress to delineate site- and time-
dependent activation of coagulation pathways in CPB
performed with IXai. In this nonhuman primate
model, the use of sensitive and specific human-based
reagents, which will delineate the extent of activation
of coagulation and fibrinolytic pathways, will be invalu-
able in determining the potential efficacy of IXai as a
clinical anticoagulant strategy.
We thank Mary Lynn Gaddis at Baxter Healthcare
Systems (Irvine, Calif.) and Dr. Steven McCormick (New
York Eye and Ear Hospital, New York, N.Y.) for per-
forming scanning electron microscopy on the arterial
filters processed after canine CPB.
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Appendix: Preparation and purification of
IXa/IXai
Factor IXai was prepared by applying Proplex (a mix-
ture of the human vitamin-K dependent coagulation
factors [factors II, VII, IX and X] supplied by Dr. Roger
Lundblad, Baxter Pharmaceuticals, Duarte, Calif.), recon-
stituted in TRIS-buffered saline solution (TBS; pH 7.5)
containing CaCl2 to a column of calcium-dependent anti-
human factor IX monoclonal antibody (CaFIX-1) coupled
to Affi-Gel 10 (BioRad Laboratories, Hercules, Calif.)
equilibrated at 4° C with TBS containing CaCl2 (0.01
mol/L). After sample application, the column was washed
extensively with TBS containing CaCl2 (0.01 mol/L) and
NaCl (0.5 mol/L), and factor IX was subsequently eluted
in TRIS-HCl (0.1 mol/L; pH 8.0) containing EDTA (0.03
mol/L). Minimal residual contaminants were then re-
moved with Q-Sepharose Fast Flow chromatography
(Pharmacia Biotech, Inc., Piscataway, N.J.). Purified fac-
tor IX (Fig. 2) was then activated at 37° C by incubation
with purified human factor XIa (1:1000 enzyme:substrate
ratio)31 in TRIS-HCl (0.05 mol/L; pH 8.0) containing
CaCl2 (0.005 mol/L) for 1 hour. Factor IX (Fig. 2) was
then activated in the presence of factor XIa, and the IXa
thus formed was reacted with a 100-fold molar excess of
dansyl-Glu-Gly-Arg chloromethylketone for 3 hours at
37° C. Dansyl-Glu-Gly-Arg chloromethylketone was pre-
pared in HCl (0.01 mol/L) at a concentration of approx-
imately 5 mg/ml and incubated with factor IXa in TBS
(final pH of the solution; 7.5). After incubation, the
mixture was dialyzed overnight at 4° C versus 20,000
volumes of phosphate-buffered saline solution. The final
product, IXai, devoid of procoagulant activity, migrated
identically to IXa on SDS-PAGE (Fig. 2) and was used for
experiments after filtration (0.2 mm) and chromatography
on DeToxi-gel columns (Pierce, Rockford, Ill.). These
preparations had no detectable lipopolysaccharide at a
protein concentration of 1 to 2 mg/ml, with the Limulus
amebocyte assay (Sigma, St. Louis, Mo.).
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